Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver

Abstract

Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.

Introduction

Traditional Japanese and Chinese herbal medicine in the treatment of chronic liver diseases has been supported by limited scientific evidence (1). In fact, available data addressing their efficacy in human conditions are commonly burdened by small study populations, inadequate controls, or insufficient endpoints. We were intrigued by the observation that keishibukuryogan (KBG), orengedokuto (OGT), and shosaikoto (SST), belonging to the family of Kampo formulas, appear to exert anti-oxidant and anti-inflammatory activities in models of liver fibrosis (2), rheumatoid arthritis (3), carcinogenesis (4), and atherosclerosis (5), in some cases superior to other anti-oxidants (6).

Obesity currently affects approximately 30% of the United States population (7) and clusters with several abnormalities related to insulin resistance, including non-alcoholic fatty liver disease (NAFLD). NAFLD represents a broad spectrum of diseases ranging from simple fatty changes to severe steatohepatitis with marked fibrosis, i.e. nonalcoholic steatohepatitis (NASH), that may progress to cirrhosis and hepatocellular carcinoma (8). What causes the transition from NAFLD to NASH remains enigmatic, and a two-hit theory has been proposed (9), with oxidative stress currently considered to provide the “second hit” on a fatty liver background (10). Based on experimental observations and prompted by the growing impact of NASH, treatments with vitamin E (VE) (11) and pioglitazone (PG) (12) have been proposed.

We thus hypothesized that the mentioned Kampo formulas might prove beneficial in a recently established cholesterol-fed non obese rabbit model of NAFLD/NASH (13). Our readouts included (i) markers of liver function, lipid and glucose metabolism; (ii) liver fibrosis and lipid contents; (iii) markers of oxidative stress; and (iv) plasma mediators of inflammation and fibrosis. Data indicate that the proposed formulas exert a protective effect at different levels, with KBG being equal or superior to currently proposed treatments.

Materials and Methods

Compounds.

VE was purchased from CLEA Japan, Inc. (Tokyo, Japan); PG was kindly provided by Takeda Pharmaceutical Co. Ltd. (Osaka, Japan). KBG (TJ-25), OGT (TJ-15), and SST (TJ-9) were obtained from Tsumura & Co. (Tokyo, Japan). Kampo formula powdered extracts were derived from a total of 16 medical plants (all registered in the Japanese Pharmacopoeia) as illustrated in Table 1.

Animal Models and Sample Collection.

Fifty-six male white rabbits (baseline weight 2 kg) were purchased at 10 weeks of age from Nippon SLC Co. (Hamamatsu, Japan) and kept in individual cages at room temperature (23 ± 1°C) under a 12-hour dark-light cycle. They were allowed an adaptation period of 2 weeks and were subsequently randomly allocated to 7 groups (8 rabbits/group) for 12 additional weeks. All groups were fed with 100g/day of standard rabbit chow (CR-3; CLEA Japan, Inc.), and in 6 groups 1% cholesterol was added. Among the latter groups, group C was not given any additional supplement or compound. The other 5 groups received 1% KBG (group KBG), 1% OGT (group OGT), 1% SST (group SST), 0.045% vitamin E (group VE), or 300 ppm PG (group PG). Treatment regimens and compounds were chosen based on previous studies from our group (6) and other laboratories (14, 15).

As mentioned above, one group (N) was fed with CR-3 only. Following the 12-week period and an overnight fasting, all rabbits were weighted and euthanized under anesthesia and tissues were collected. These included urine, blood (from the inferior vena cava), and liver (perfused with physiological saline and dissected). All procedures complied with the current guidelines for the care and use of laboratory animals, and the protocol was approved by the Committee on Animal Experimentation of the University of Toyama.

Plasma Markers for Lipid and Glucose Metabolism and Liver Injury.

Plasma total cholesterol (T-chol), high-density lipoprotein cholesterol (HDL-chol), low-density lipoprotein cholesterol (LDL-chol), triglyceride (TG), free fatty acid (FFA), serum aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were measured in all samples using routine methods. Hyaluronic acid (HA) levels were also tested as markers of fibrosis following methods described elsewhere (16). Plasma insulin and glucose levels were determined by Insulin ELISA Kit, Ultra Sensitive (Morinaga Institute of Biological Science, Inc., Yokohama, Japan) and Antisense III (Horiba, Ltd., Kyoto, Japan), respectively.

Plasma Adipocytokines and TGF-β1.

Adipocytokines (i.e. leptin, adiponectin) play an important role in the liver and peripheral glucose and lipid metabolism (17) as well as in liver fibrosis (18), and they have been suggested as critical factors in NASH development (19). Plasma samples were analyzed for leptin and adiponectin using commercially available kits (Multi-Species Leptin RIA Kit, Linco Research Inc., Saint Charles, MO; Adiponectin ELISA Kit, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). Transforming growth factor-β1 (TGF-β1) is an established mediator for fibrosis development, and its levels have been correlated with NASH onset (11). All plasma samples were analyzed for TGF-β1 following activation of the latent form to an immunoreactive one using 2.5 M acetic acid and 10 M urea followed by 2.7 N and 1 M HEPES. Activated samples were then diluted and analyzed using a quantitative sandwich enzyme immunoassay technique with recombinant human TGF-β1 soluble receptor type II onto a microplate (R&D System Inc., Minneapolis, MN). Optical densities were then measured at 450 nm and the concentration of TGF-β1 determined on a standard curve.

Markers of Oxidative Stress.

The degree of oxidative stress was evaluated by measuring levels of plasma and hepatic lipid peroxide (LPO) and urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG). Liver samples were first weighed and minced in ice-cold PBS (pH 7.4), then homogenized at a ratio of 1:10 (w:v). Following centrifugation at 3,000 g for 10 minutes at 4°C, supernatants were collected and used for the analysis. LPO levels were determined using a lipid peroxidation assay kit (Determinant LPO: Kyowa Medex Co., Tokyo, Japan). Urine samples were centrifuged at 10,000 g for 15 minutes and the supernatants used for 8-OHdG measurement by competitive ELISA (Japan Institute for the Control of Aging, Fukuroi, Japan). Urinary creatinine was also determined using standard methods to allow the appropriate corrections of 8-OHdG levels.

Liver Lipid Content and Fibrosis.

For lipid content determination, liver samples were homogenized and lipids extracted using a mixture of chloroform and methanol (2:1, v:v) to subsequently analyze the amount of T-chol and free cholesterol, TG and FFA using commercially available kits (Triglyceride, Cholesterol, Free cholesterol, and NEFA tests, all from Wako Pure Chemical Ind., Ltd., Osaka, Japan). Sections (5-μm-thick) of formalin-fixed and paraffin-embedded liver tissues were obtained from each experimental animal. The degree of fibrosis was quantitated through the tissue density of activated hepatic stellate cells (HSCs) and the expression of α-smooth muscle actin (α-SMA). HSCs were stained using a mouse monoclonal anti-macrophage antibody (DAKO Cytomation Co., Glostrup, Denmark) and guinea pig polyclonal anti adipocyte differentiation-related protein (ADRP) antibody (Progen Biotechnik, Heidelberg, Germany) as previously described (13), and cells were counted in three microscopic fields (×400). For the study of α-SMA expression, a specific murine monoclonal antibody was purchased from DAKO Cytomation Co. and used for immunohistochemistry. Areas of α-SMA positive lesions were evaluated in 6 microscopic fields (×40) per specimen and expressed as the percentage of the total area of the fields. For both HSC count and the α-SMA expression study, two independent pathologists blindly evaluated all samples.

Statistical Analysis.

All continuous variables are expressed as mean ± standard error of measurement (SEM). To compare the efficacy of Kampo formulas with other treatments, pairwise comparisons between groups C, VE, and PG and each of the other three groups were performed by establishing one-way analysis of variance models for multiple comparison tests (Bonferroni). All analyses were two-tailed, and P values < 0.05 were considered as statistically significant. Importantly, all comparisons were performed blindly as to the treatments corresponding to each group. Statistical analyses were performed using Intercooled Stata 8.0 (Stata Corp, College Station, TX).

Results

Body Weight and Liver/Body Weight Ratio.

To ascertain if the used supplementations had an effect on lipid adsorption and on body and liver weight, these variables were compared among groups at the end of the treatment (Table 2). Cholesterol-fed groups had similar body weight, in all cases significantly lower than group N. Similarly, all cholesterol-fed groups showed higher liver/body weight ratios compared to group N.

Plasma Markers for Lipid and Glucose Metabolism and Liver Injury.

Table 2 illustrates the plasma lipid profiles at the end of the study in each treatment group. Importantly, T-chol levels in group C were significantly higher compared to each of the other supplemented groups (P < 0.01 for all comparisons), and the KBG group had the lowest T-chol levels with the expected exception of the group receiving neither cholesterol nor treatments. Data on LDL-chol and FFA also manifested the same degree of significance, while levels of HDL-chol and TG failed to reach statistically significant differences. As for glucose metabolism and biochemical signs of liver injury (Table 3 ), no significant differences were observed between treatment groups in fasting glucose or insulin levels and transaminase (AST, ALT) activities.

Serum HA, Plasma Adipocytokines, and TGF-β1.

Serum levels of HA were significantly lower in groups KBG and N compared to group C, while other differences were not statistically significant (Table 3 ). Plasma levels of TGF-β1 following PG treatment were significantly lower compared to group C, while no significant differences were observed among groups for leptin levels (Table 3 ). When adiponectin levels were compared, KBG was the only supplement associated with significantly higher levels compared to group C (Table 3 ).

Markers of Oxidative Stress.

With the exception of group N, group KBG was the only group with significantly lower plasma LPO levels compared to group C (Fig. 1A ), while such significant difference was observed in liver tissue levels with KBG superior to PG or VE (Fig. 1B ). Urinary amounts of 8-OHdG were significantly lower in the KBG, VE and PG supplement groups compared to group C (Fig. 1C ).

Liver Lipid Content and Fibrosis.

Lipid contents in the liver tissue from all experimental groups are shown in Table 4 . KBG treatment was associated with the lowest levels of T-chol, free cholesterol, and TG. Importantly, KBG treatment was also associated with significantly lower T-chol and free cholesterol, FFA and TG compared to PG, while the former three variables also manifested significant decreases in KBG compared to VE. Figure 2 illustrates the distribution of α-SMA immuno-positive areas as an index of HSC activation in representative liver tissues from each of the 7 study groups. Such areas were virtually absent in group N (Fig. 2A ) while being well represented in group C (Fig. 2B ). Using semi-quantitative analysis, we observed that all groups had lower representation of α-SMA positive areas per microscopy field compared to group C, while KBG treatment led also to significantly lower cell prevalence compared to groups PG and VE (Fig. 2H ). Furthermore, our double immunohistochemical staining for HSCs (Fig. 3A ) demonstrated that these cells were less represented in liver tissues from groups KBG and OGT compared to group C. Importantly, groups KBG and OGT had significantly lower values of HSCs compared to both VE or PG supplementations, with the latter surprisingly higher than group C (Fig. 3B ).

Discussion

We report herein for the first time a comprehensive set of rigorous data supporting that traditional Japanese Kampo formulas appear as effective preventive treatments for NASH development in a non obese rabbit model. Importantly, such results are consistent in all our study endpoints representative of the features of the disease and favorably compare to currently supported treatments (i.e. VE, PG). Among Kampo formulas, KBG induced the largest amelioration in nearly all analyzed features, and in several readouts KBG was superior to VE and PG.

The use of Japanese and Chinese traditional herbal medicine for human diseases is becoming more common (20) despite being often supported by scanty or poorly reproducible scientific evidence. In fact, the conclusions of most available studies are limited by several methodological flaws (21). For these reasons, and based on preliminary in vitro data, we performed an extensive blind analysis of the effects of Kampo formulas in a liver disease animal model and report for the first time their efficacy in ameliorating NASH features.

Although what causes the transition from NAFLD to NASH remains largely unknown, a current concept involves a “two-hit” hypothesis in which an initial metabolic disturbance (represented by lipid and glucose dysregulation) induces the fatty liver onset; a second pathogenic stimulus leads to oxidative stress and ultimately NASH with inflammation and fibrosis (9). The transition might be mediated by HSC activation by reactive oxygen species, and our observation that all tested supplements led to lower levels of HSC activation in the areas of α-SMA positive lesions supports this thesis (Fig. 2). Similarly, all supplements except PG produced similar changes of the HSC phenotype compatible with an anti-fibrotic effect. The reasons for the PG discrepancy can currently be only hypothesized in the fact that its peroxisome proliferators-activated receptor γ (PPAR-γ) agonist activity might inhibit the activation of quiescent HSCs to be myofibroblast-like cells (22). The fact that PPAR-γ expression is a sign of the phenotypic switch from activated to quiescent HSCs (23) also strengthens this view. Further, our data cumulatively support the existence of different mechanism pathways for Kampo formulas and other proposed NAFLD treatments such as PG. It is of note that the α-SMA positive area in the group treated with KBG was significantly lower than in animals treated with VE or PG, thus indicating a stronger effect of this Kampo formula on preventing liver fibrosis. The anti-fibrotic effect of Kampo formulas had been previously suggested by Shimizu and colleagues reporting that SST inhibited lipid peroxidation in hepatocytes and HSCs in a rat liver fibrosis model (2), while others demonstrated that SST prevented fibrosis by inhibiting the activation of HSCs in a diet-induced rat NASH model (24). We also submit that additional pathology changes were observed in treated groups, including hepatocellular fat deposition, megamitochondria and hepatocellular ballooning with Mallory bodies, but fibrosis was the prominent observation and was thus used for comparisons.

One major issue raised by these data is based on the need to identify what components of Kampo formulas are ultimately effective and produce the observed changes. While we cannot provide an answer to this critical question, we can surmise some directions from previous reports. For example, the tannins found in berries as well as in KBG components (25, 26) are known to be potent anti-oxidants (27). Similarly, other substances (baicalein, baicalin, wogonin) or herbs (Coptidis rhizoma and Phellodendri cortex) found in OGT and SST also exert a scavenging activity (28, 29). We are also aware of the possibility that multiple Kampo formulas might produce a synergistic effect when supplemented or that a dose-dependent effect might apply, but we are convinced that, for scientific purposes, the priority in future studies will be dedicated to the search for the active compounds.

Notably, nearly all measured parameters manifested similar degrees of improvement using KBG, with the possible exception of the glucose metabolism that was characterized by non significant changes in all groups. On the other hand, KBG markedly influenced the lipid profiles that commonly characterize NAFLD, as mainly indicated by the reduced plasma T-chol levels. Previous reports had demonstrated a similar activity for KBG in a rat model of diabetic nephropathy (30) as well as its preventive effectiveness on atherosclerosis in cholesterol-fed rabbits (6). On a different level, the observed effect of Kampo formulas on adipocytokines is a novel observation since data on these molecules in NASH are limited to tumor necrosis factor α (TNF-α) expression (31) and leptin levels (32) as proinflammatory indicators. While we did not measure TNF-α expression, we could not recapitulate the reported differences in leptin levels, possibly because of the lack in our model of obesity and hyperinsulinemia, two major determinants of leptin levels (33). On the other hand, adiponectin is a metabolic mediator produced by adipocytes, and its plasma levels were shown to be reduced in patients with NAFLD (34). Adiponectin in fact appears to play a role in liver injury development (35), possibly by protecting against oxidative stress (36) and inflammation (37). This is also supported by the activity of several pharmacological compounds (including PG) used in the metabolic syndrome that increase adiponectin plasma levels (38), thus suggesting that adiponectin might ultimately constitute an effective target for NASH therapies (39). In our experimental model, PG supplementation did not induce significant changes, possibly due to the lack of insulin resistance and obesity that mediate adiponectin levels (40). On the other hand, only KBG induced a significant increase in adiponectin levels, despite the similar body weights among groups. This effect might then be explained with the observed changes in the lipid contents in the examined liver tissues from model rabbits. Quite surprisingly, liver FFA content was significantly higher in the PG-treated group compared to group C, and the significance of this observation remains unclear. We can only hypothesize that increased blood glucose levels and body fat mass might play a role (12, 41) or that new interactions between metabolic and inflammatory pathways should be identified, similar to what was reported in autoimmune diseases (42, 43).

One limitation of the present rabbit model for the metabolic syndrome is the absence of obesity, insulin resistance, and hypertransaminasemia. However, clinical data suggest that these conditions do not consistently associate with NASH, with frequently encountered lean patients (44) with no transaminase elevation (45). In contrast, liver pathology is the ultimate criterion for fatty liver diagnosis. To this extent, we submit that a major strength of this model is in the liver histology that includes fatty and inflammatory changes as well as extensive perivenular and pericellular fibrosis, resembling the unique features of human NASH. Finally, we hypothesize that longer observations might produce different features and reproduce other NASH features such as frank cirrhosis and possibly liver cancer.

The collected evidence appears to indicate that Kampo formulas in general and KBG in particular are effective in exerting a protective effect in the NAFLD establishment as well as the transition to NASH, that is, both “hits” of the disease pathogenesis. This hypothesis will warrant further studies in other animal models manifesting also obesity and insulin resistance before pilot human data are sought. In fact, data obtained in animal models, particularly for NASH, might prove non applicable to humans in the clinical practice, particularly in terms of efficacy, while the plethora of animal models (46) proposed thus far paradoxically contributes to make the picture less clear. Furthermore, researchers in other phenotypes of the metabolic syndrome are encouraged to investigate the effects of Kampo formulas on other outcomes (i.e. cardiovascular events). In fact, a growing fund of knowledge is recently stressing the importance of comorbidities in the resulting scenario, as it appears to be the case for intermittent hypoxia from obstructive sleep apnea (47) or new effector mechanisms (48). In conclusion, we acknowledge that a pharmacological approach to slowly progressing diseases such as NAFLD and NASH must be primarily preventive, and we submit that Kampo formulas are an excellent candidate for future studies, particularly considering the paucity of side effects observed in other clinical settings (49) and the need for prolonged treatments.

Table 1.
Medicinal Plants and Weight (g) Used to Obtain Keishibukuryogan (KBG, TJ-25), Orengedokuto (OGT, TJ-15) and Shosaikoto (SST, TJ-9)

KBG Weight (g)

Cinnamomi cortex Cinnamomum cassia Blume 3.0

Paeoniae radix Paeonia lactiflora Pallas 3.0

Persicae semen Prunus persica Batsch 3.0

Hoelen Poria cocos Wolf 3.0

Moutan cortex Paeonia suffruticosa Andrews 3.0

OGT

Scutellariae radix Scutellaria baicalensis Georgi 3.0

Coptidis rhizoma Coptis japonica Makino 2.0

Gardeniae fructus Gardenia jasminoides Ellis 2.0

Phellodendri cortex Phellodendron amurense Ruprecht 1.5

SST

Bupleuri radix Bupleurum falcatum Linné 7.0

Pinelliae tuber Pinellia ternata Breitenbach 5.0

Scutellariae radix Scutellaria baicalensis Georgi 3.0

Zizyphi fructus Zizyphus jujuba Miller 3.0

Ginseng radix Panax ginseng C.A. Meyer 3.0

Glycyrrhizae radix Glycyrrhiza uralensis Fischer 2.0

Zingiberis rhizoma Zingiber officinale Roscoe 1.0

Table 2.
Body Weight, Liver/Body Weight Ratio, and Lipid Metabolism in the 7 Experimental Groups^a

Parameters N C KBG OGT SST VE PG

^a T-chol, total cholesterol; HDL-chol, high-density lipoprotein cholesterol; LDL-chol, low-density lipoprotein cholesterol; TG, triglyceride; FFA, free fatty acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.

^b P < 0.01 vs. group C.

^c P < 0.01 vs. group VE.

^d P < 0.01 vs. group PG.

Body weight (kg) 3.42 ± 0.06^b,c 2.90 ± 0.05 2.97 ± 0.08 2.95 ± 0.03 2.81 ± 0.05 3.02 ± 0.09 3.09 ± 0.05

% Liver/body wt 2.8 ± 0.1^b 4.1 ± 0.2 3.7 ± 0.2 3.7 ± 0.1 5.3 ± 0.2^b,c,d 4.2 ± 0.2 3.6 ± 0.1

T-chol (mg/dL) 19 ± 2^b,c 1999 ± 276 675 ± 159^b 960 ± 145^b 1227 ± 128^b 1213 ± 178^b 1293 ± 76^b

HDL-chol (mg/dL) 13.0 ± 2.0 16.4 ± 3.8 16.9 ± 2.2 14.6 ± 1.9 15.9 ± 1.4 16.5 ± 3.0 12.6 ± 2.0

LDL-chol (mg/dL) 5.0 ± 0.8^b,c 741.6 ± 69.5 307.1 ± 54.3^b,d 423.1 ± 46.4^b 494.0 ± 61.3^b 426.1 ± 50.4^b 568.8 ± 39.1

TG (mg/dL) 37.8 ± 10.8 69.1 ± 24.5 52.3 ± 17.7 45.9 ± 13.1 98.6 ± 23.4 58.8 ± 16.6 46.9 ± 13.6

FFA (mEq/L) 0.28 ± 0.02^b 0.64 ± 0.11 0.39 ± 0.03^b 0.35 ± 0.03^b 0.28 ± 0.03^b 0.32 ± 0.03^b 0.32 ± 0.02^b

Table 3.
Profiles of Glucose Metabolism, Liver Injury, TGF-β1, Leptin, Hyaluronic Acid, and Adiponectin Levels in the 7 Experimental Groups^a

Parameters N C KBG OGT SST VE PG

^a AST, aspartate aminotransferase; ALT, alanine aminotransferase; TGF-β1, transforming growth factor-β1; HA, hyaluronic acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.

^b P < 0.01 vs. group C.

^c P < 0.05 vs. group C.

^d P < 0.001 vs. group C.

Fasting plasma glucose (mg/dL) 161.6 ± 36.4 120.4 ± 6.4 117.8 ± 7.7 138.1 ± 7.8 121.8 ± 3.5 151.9 ± 19.1 181.3 ± 17.0

Insulin (ng/mL) 244.0 ± 74.8 237.9 ± 71.4 183.1 ± 48.5 170.8 ± 56.4 329.9 ± 57.6 383.8 ± 151.9 209.9 ± 82.9

AST (IU/L) 50.0 ± 13.2 31.5 ± 3.1 55.4 ± 18.5 30.1 ± 3.0 37.6 ± 4.2 41.8 ± 6.8 37.5 ± 5.0

ALT (IU/L) 54.0 ± 11.5 58.6 ± 8.5 56.4 ± 11.8 45.8 ± 7.8 56.0 ± 14.9 49.3 ± 7.4 44.5 ± 4.7

TGF-β1 (pg/mL) 1.22 ± 0.17^b 1.71 ± 0.12 1.40 ± 0.12 1.29 ± 0.12 1.22 ± 0.06 1.37 ± 0.14 1.12 ± 0.10^b

Leptin (ng/mL) 2.30 ± 0.28 2.06 ± 0.18 1.66 ± 0.27 1.79 ± 0.29 2.57 ± 0.11 1.89 ± 0.25 1.93 ± 0.27

HA (pg/mL) 25.03 ± 5.77^d 214.91 ± 33.03 93.03 ± 15.56^c 115.31 ± 17.29 214.73 ± 32.51 117.11 ± 28.19 171.13 ± 28.91

Adiponectin (mg/mL) 266.88 ± 48.50 176.69 ± 17.94 415.50 ± 69.74^c 340.88 ± 49.70 220.75 ± 15.12 260.63 ± 45.62 272.13 ± 56.42

Table 4.
Liver Lipid Contents in the 7 Experimental Groups^a

Parameters N C KBG OGT SST VE PG

^a T-chol, total cholesterol; TG, triglyceride; FFA, free fatty acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.

^b P < 0.01 vs. group C.

^c P < 0.01 vs. VE.

^d P < 0.01 vs. PG.

T-chol (mg/g liver) 3.41 ± 0.08^b 21.65 ± 3.70 11.05 ± 2.10^b,c,d 14.58 ± 2.63 16.14 ± 1.32 21.07 ± 1.21 21.39 ± 1.67

TG (mg/g liver) 7.26 ± 0.90^d 9.95 ± 0.81 6.99 ± 0.60^d 8.45 ± 1.10 11.98 ± 0.46 10.11 ± 0.73 11.21 ± 0.53

Free cholesterol (mg/g liver) 4.36 ± 0.10^b 11.21 ± 1.72 4.82 ± 1.29^b,c,d 6.56 ± 1.44^b,d 10.14 ± 0.57 10.11 ± 0.73 13.59 ± 0.94

FFA (10³³ mEq/g liver) 4.00 ± 0.13 6.69 ± 0.54 5.28 ± 0.72^c,d 4.66 ± 0.67 8.03 ± 0.98 9.61 ± 0.90 10.85 ± 1.02^b

Figure 1.
Lipid peroxide (LPO) plasma (A) and liver tissue (B) levels and urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels (C) at the end of the study period. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N. Pairwise comparisons were performed between Kampo formulas and groups C, VE and PG, and P values were corrected for multiple testing.

Figure 2.
Alpha-smooth muscle actin (α-SMA) immunohistochemical findings in the liver tissue (×40) at the end of the study period. Groups: N (A) and C (B), no supplement; KBG, keishibukuryogan (C); OGT, orengedokuto (D); SST, shosaikoto (E); VE, vitamin E (F); PG, pioglitazone (G). All groups were fed with standard chow with 1% cholesterol except for group N. α-SMA immuno-positivity was not observed in the rabbits of group N. α-SMA immuno-positive areas are extended in the perivenular area in the rabbits of group C. α-SMA immuno-positive areas appear in the rabbits of groups KBG, OGT, SST, VE and PG, but they are milder than group C. H illustrates the percentage of α-SMA positive area evaluated by computer-assisted semi-quantitative analysis. Values are expressed as mean ± SEM. Pairwise comparisons were performed between Kampo formulas and C, VE and PG groups, and P values were corrected for multiple testing; for all comparisons of group C vs. other groups, P<0.001 (not shown).

Figure 3.
Double immunostaining (A, magnification ×400) for hepatic stellate cells (HSCs) using adipocyte differentiation-related protein (ADRP, circles) brown and macrophage blue staining (arrows). Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglita-zone. The number of HSCs showing single ADRP staining in the liver tissue of all groups is illustrated in B. Values are expressed as mean ± SEM. Pairwise comparisons were performed between Kampo formulas and groups C, VE and PG, and P values were corrected for multiple testing.

Parameters	N	C	KBG	OGT	SST	VE	PG
^a T-chol, total cholesterol; HDL-chol, high-density lipoprotein cholesterol; LDL-chol, low-density lipoprotein cholesterol; TG, triglyceride; FFA, free fatty acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.
^b P < 0.01 vs. group C.
^c P < 0.01 vs. group VE.
^d P < 0.01 vs. group PG.
Body weight (kg)	3.42 ± 0.06^b,c	2.90 ± 0.05	2.97 ± 0.08	2.95 ± 0.03	2.81 ± 0.05	3.02 ± 0.09	3.09 ± 0.05
% Liver/body wt	2.8 ± 0.1^b	4.1 ± 0.2	3.7 ± 0.2	3.7 ± 0.1	5.3 ± 0.2^b,c,d	4.2 ± 0.2	3.6 ± 0.1
T-chol (mg/dL)	19 ± 2^b,c	1999 ± 276	675 ± 159^b	960 ± 145^b	1227 ± 128^b	1213 ± 178^b	1293 ± 76^b
HDL-chol (mg/dL)	13.0 ± 2.0	16.4 ± 3.8	16.9 ± 2.2	14.6 ± 1.9	15.9 ± 1.4	16.5 ± 3.0	12.6 ± 2.0
LDL-chol (mg/dL)	5.0 ± 0.8^b,c	741.6 ± 69.5	307.1 ± 54.3^b,d	423.1 ± 46.4^b	494.0 ± 61.3^b	426.1 ± 50.4^b	568.8 ± 39.1
TG (mg/dL)	37.8 ± 10.8	69.1 ± 24.5	52.3 ± 17.7	45.9 ± 13.1	98.6 ± 23.4	58.8 ± 16.6	46.9 ± 13.6
FFA (mEq/L)	0.28 ± 0.02^b	0.64 ± 0.11	0.39 ± 0.03^b	0.35 ± 0.03^b	0.28 ± 0.03^b	0.32 ± 0.03^b	0.32 ± 0.02^b

Parameters	N	C	KBG	OGT	SST	VE	PG
^a AST, aspartate aminotransferase; ALT, alanine aminotransferase; TGF-β1, transforming growth factor-β1; HA, hyaluronic acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.
^b P < 0.01 vs. group C.
^c P < 0.05 vs. group C.
^d P < 0.001 vs. group C.
Fasting plasma glucose (mg/dL)	161.6 ± 36.4	120.4 ± 6.4	117.8 ± 7.7	138.1 ± 7.8	121.8 ± 3.5	151.9 ± 19.1	181.3 ± 17.0
Insulin (ng/mL)	244.0 ± 74.8	237.9 ± 71.4	183.1 ± 48.5	170.8 ± 56.4	329.9 ± 57.6	383.8 ± 151.9	209.9 ± 82.9
AST (IU/L)	50.0 ± 13.2	31.5 ± 3.1	55.4 ± 18.5	30.1 ± 3.0	37.6 ± 4.2	41.8 ± 6.8	37.5 ± 5.0
ALT (IU/L)	54.0 ± 11.5	58.6 ± 8.5	56.4 ± 11.8	45.8 ± 7.8	56.0 ± 14.9	49.3 ± 7.4	44.5 ± 4.7
TGF-β1 (pg/mL)	1.22 ± 0.17^b	1.71 ± 0.12	1.40 ± 0.12	1.29 ± 0.12	1.22 ± 0.06	1.37 ± 0.14	1.12 ± 0.10^b
Leptin (ng/mL)	2.30 ± 0.28	2.06 ± 0.18	1.66 ± 0.27	1.79 ± 0.29	2.57 ± 0.11	1.89 ± 0.25	1.93 ± 0.27
HA (pg/mL)	25.03 ± 5.77^d	214.91 ± 33.03	93.03 ± 15.56^c	115.31 ± 17.29	214.73 ± 32.51	117.11 ± 28.19	171.13 ± 28.91
Adiponectin (mg/mL)	266.88 ± 48.50	176.69 ± 17.94	415.50 ± 69.74^c	340.88 ± 49.70	220.75 ± 15.12	260.63 ± 45.62	272.13 ± 56.42

Parameters	N	C	KBG	OGT	SST	VE	PG
^a T-chol, total cholesterol; TG, triglyceride; FFA, free fatty acid. Values are expressed as mean ± SEM. Groups: N and C, no supplement; KBG, keishibukuryogan; OGT, orengedokuto; SST, shosaikoto; VE, vitamin E; PG, pioglitazone. All groups were fed with standard chow with 1% cholesterol except for group N.
^b P < 0.01 vs. group C.
^c P < 0.01 vs. VE.
^d P < 0.01 vs. PG.
T-chol (mg/g liver)	3.41 ± 0.08^b	21.65 ± 3.70	11.05 ± 2.10^b,c,d	14.58 ± 2.63	16.14 ± 1.32	21.07 ± 1.21	21.39 ± 1.67
TG (mg/g liver)	7.26 ± 0.90^d	9.95 ± 0.81	6.99 ± 0.60^d	8.45 ± 1.10	11.98 ± 0.46	10.11 ± 0.73	11.21 ± 0.53
Free cholesterol (mg/g liver)	4.36 ± 0.10^b	11.21 ± 1.72	4.82 ± 1.29^b,c,d	6.56 ± 1.44^b,d	10.14 ± 0.57	10.11 ± 0.73	13.59 ± 0.94
FFA (10³³ mEq/g liver)	4.00 ± 0.13	6.69 ± 0.54	5.28 ± 0.72^c,d	4.66 ± 0.67	8.03 ± 0.98	9.61 ± 0.90	10.85 ± 1.02^b

Footnotes

The study was supported by a Grant-in-Aid for the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Acknowledgements

The authors are grateful to Tokimasa Kumada and Hideki Hatta for their technical assistance.

References

Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N, Kanda T. Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 34:231–239, 2006.

Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29:149–160, 1999.

Nozaki K, Hikiami H, Goto H, Nakagawa T, Shibahara N, Shimada Y. Keishibukuryogan (gui-zhi-fu-ling-wan), a kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis. Evid Based Complement Alternat Med 3: 359–364, 2006.

Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kishimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′-deoxyguanosine formation. Hepatology 35:1125–1133, 2002.

Sekiya N, Tanaka N, Itoh T, Shimada Y, Goto H, Terasawa K. Keishi-bukuryo-gan prevents the progression of atherosclerosis in cholesterol-fed rabbit. Phytother Res 13:192–196, 1999.

Sekiya N, Kainuma M, Hikiami H, Nakagawa T, Kouta K, Shibahara N, Shimada Y, Terasawa K. Oren-gedoku-to and Keishi-bukuryo-gan-ryo inhibit the progression of atherosclerosis in diet-induced hyper-cholesterolemic rabbits. Biol Pharm Bull 28:294–298, 2005.

Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727, 2002.

Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99–S112, 2006.

Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastro-enterology 114:842–845, 1998.

10.

Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281:G1135–1139, 2001.

11.

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15:1667–1672, 2001.

12.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307, 2006.

13.

Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, Terasawa K, Shimada Y. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 41:971–980, 2006.

14.

Chen MF, Hsu HC, Liau CS, Lee YT. The role of vitamin E on the anti-atherosclerotic effect of fish oil in diet-induced hypercholesterolemic rabbits. Prostaglandins Other Lipid Mediat 57:99–111, 1999.

15.

Moroe H, Fujii H, Honda H, Arai K, Kanazawa M, Notoya Y, Kogo H. Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. Eur J Pharmacol 497:317–325, 2004.

16.

Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25:779–786, 2005.

17.

Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes 55 Suppl 2: S145–154, 2006.

18.

Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37:206–213, 2002.

19.

Kowdley KV, Pratt DS. Adiponectin—tipping the scales from NAFLD to NASH? Gastroenterology 128:511–513, 2005; author reply 513.

20.

Cohen MH. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatol Ther 16:77–84, 2003.

21.

Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol 24:5457–5464, 2006.

22.

Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350:385–391, 2006.

23.

Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279:11392–11401, 2004.

24.

Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 28:298–306, 1998.

25.

Yokozawa T, Chen CP, Tanaka T. Direct scavenging of nitric oxide by traditional crude drugs. Phytomedicine 6:453–463, 2000.

26.

Satoh K, Nagai F, Ushiyama K, Yasuda I, Seto T, Kano I. Inhibition of Na+, K(+)-ATPase by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, a major constituent of both moutan cortex and Paeoniae radix. Biochem Pharmacol 53:611–614, 1997.

27.

Heinonen M. Antioxidant activity and antimicrobial effect of berry phenolics—a Finnish perspective. Mol Nutr Food Res 51:684–691, 2007.

28.

Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1472:643–650, 1999.

29.

Choi DS, Kim SJ, Jung MY. Inhibitory activity of berberine on DNA strand cleavage induced by hydrogen peroxide and cytochrome c. Biosci Biotechnol Biochem 65:452–455, 2001.

30.

Nakagawa T, Yokozawa T, Terasawa K, Nakanishi K. Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy. J Pharm Pharmacol 55:219–227, 2003.

31.

Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158–1163, 2001.

32.

Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95: 3584–3589, 2000.

33.

Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 143: 293–311, 2000.

34.

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40:46–54, 2004.

35.

Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796–1807, 2003.

36.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–1295, 2002.

37.

Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 40:19–22, 2004.

38.

Yang G, Li L, Tang Y, Boden G. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. Biochem Biophys Res Commun 339:1190–1196, 2006.

39.

Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 44:253–261, 2006.

40.

Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817–30822, 2004.

41.

Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46:424–429, 2007.

42.

Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75, 2007.

43.

Duhalde-Vega M, Loureiro ME, Mathieu PA, Retegui LA. The peptide specificities of the autoantibodies elicited by mouse hepatitis virus A59. J Autoimmun 27:203–209, 2006.

44.

Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112–117, 2000.

45.

Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152, 2004.

46.

Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 38:203–217, 2005.

47.

Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 45:1007–1013, 2007.

48.

Shternhall-Ron K, Quintana FJ, Perl S, Meivar-Levy I, Barshack I, Cohen IR, Ferber S. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 28:134–142, 2007.

49.

Kobayashi H, Mizuno N, Teramae H, Kutsuna H, Ueoku S, Onoyama J, Yamanaka K, Fujita N, Ishii M. Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety. Drugs Exp Clin Res 30:197–202, 2004.

KBG		Weight (g)
Cinnamomi cortex	Cinnamomum cassia Blume	3.0
Paeoniae radix	Paeonia lactiflora Pallas	3.0
Persicae semen	Prunus persica Batsch	3.0
Hoelen	Poria cocos Wolf	3.0
Moutan cortex	Paeonia suffruticosa Andrews	3.0
OGT
Scutellariae radix	Scutellaria baicalensis Georgi	3.0
Coptidis rhizoma	Coptis japonica Makino	2.0
Gardeniae fructus	Gardenia jasminoides Ellis	2.0
Phellodendri cortex	Phellodendron amurense Ruprecht	1.5
SST
Bupleuri radix	Bupleurum falcatum Linné	7.0
Pinelliae tuber	Pinellia ternata Breitenbach	5.0
Scutellariae radix	Scutellaria baicalensis Georgi	3.0
Zizyphi fructus	Zizyphus jujuba Miller	3.0
Ginseng radix	Panax ginseng C.A. Meyer	3.0
Glycyrrhizae radix	Glycyrrhiza uralensis Fischer	2.0
Zingiberis rhizoma	Zingiber officinale Roscoe	1.0